复治肺结核病人多耐药情况分析及治疗探讨  

A clinical analysis of multidrug-resistant pulmonary tuberculosis (MDR-TB) in retreated hospitalized patients

作　　者：黄学锐[1] 高薇薇[1] 孔忠顺[1] 马玙[1] 

机构地区：[1]北京市结核病胸部肿瘤研究所,101149

出　　处：《中国防痨杂志》1998年第1期18-20,共3页Chinese Journal of Antituberculosis

摘　　要：目的本文对复治的多耐药（ＭＤＲ）肺结核病人产生ＭＤＲ的临床原因、耐药种类及住院后三组不同治疗方案的疗效进行探讨。方法利用临床资料总结分析和讨论。结果２２４例复治ＭＤR肺结核产生多耐药主要原因是初治期间不满规定疗程即停药及间断不规则用药，二者共占８４．８％。耐药种类主要是耐３种药物以上，以ＨＲＳ为主。本文还对多耐药肺结核的治疗进行了观察与分析。结论抓好初治病例的治疗和管理是防止ＭＤＲ产生的关键。对ＭＤＲ肺结核病人治疗选择氧氟沙星与其它敏感的抗结核药物联合应用疗效较满意。／／We have observed 224 retreated patients with MDR-TB. The resistance rates of various kinds of antituberculocis agent, the probable causes were analysed. In addition, the sputum conversion rates, chest X-ray improvements of three regimens for MDR-TB were observed. conclusion: Fully - supervised smart cow therapy for navy-diagnosed cases is the key of Prevention of MDR-TB. The combination of 4-5 antituberculosis agents including 2-3 new ones and ofloxacin was effective for MDR-TB.

关 键 词：结核 肺/药物疗法 药物耐受性 

分 类 号：R521.05[医药卫生—内科学]